Clinical Trial Update: An Exploratory Clinical Study of Nimotuzumab in Bladder - Sparing Chemoradiotherapy for Muscle - Invasive Bladder Cancer [Phase 1]

View source ↗

Summary

An exploratory Phase 1 study evaluating nimotuzumab in bladder-sparing chemoradiotherapy for muscle-invasive bladder cancer; the trial is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• Nimotuzumab (nimotuzumab)

Snippet

Sponsor: Peking University First Hospital | Conditions: Bladder (Urothelial, Transitional Cell) Cancer | Phase 1 | Status: NOT_YET_RECRUITING